{"preliminary_commentary":{"by_channel":{"x_thread":8,"youtube":7,"podcast":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02290951\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["odronextamab"]],"indication":"previously treated CD20-positive B-cell malignancies","name":"ELM-1","nct_id":"NCT02290951","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=elm-1-nct02290951. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ELM-1","arms":[{"description":"DLBCL post CAR-T","label":"Part A","type":"EXPERIMENTAL"},{"description":"FL","label":"1N Part B","type":"EXPERIMENTAL"},{"description":"DLBCL","label":"2N Part B","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-08-21","type":"ACTUAL"},"conditions":["Non-Hodgkin Lymphoma","Chronic Lymphocytic Leukemia"],"enrollment":{"count":200,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Odronextamab multiple dose levels","otherNames":["REGN1979"],"type":"DRUG"},{"name":"Odronextamab multiple dose levels","otherNames":["REGN1979"],"type":"DRUG"}],"last_update":"2025-10-10","lead_sponsor":"Regeneron Pharmaceuticals","official_title":"An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy (ELM-1)","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2025-08-21","type":"ACTUAL"},"primary_outcomes":[{"measure":"Safety/overall frequency of adverse events (AEs)","timeFrame":"Up to 24 months"},{"measure":"Safety/dose limiting toxicities (DLTs)","timeFrame":"Up to 28 days"},{"measure":"Antitumor activity as measured by the objective response rate (ORR)","timeFrame":"Through study completion, an average of 24 months"}],"references":[{"citation":"Bayly-McCredie E, Prince HM, Yannakou CK, Fiorenza S. An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma. Expert Opin Biol Ther. 2025 Apr;25(4):331-343. doi: 10.1080/14712598.2025.2479631. Epub 2025 Mar 24.","pmid":"40106587","type":"DERIVED"},{"citation":"Topp MS, Matasar M, Allan JN, Ansell SM, Barnes JA, Arnason JE, Michot JM, Goldschmidt N, O'Brien SM, Abadi U, Avivi I, Cheng Y, Flink DM, Zhu M, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Crombie JL. Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study. Blood. 2025 Apr 3;145(14):1498-1509. doi: 10.1182/blood.2024027044.","pmid":"39786390","type":"DERIVED"},{"citation":"Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chavez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS. Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339. doi: 10.1016/S2352-3026(22)00072-2. Epub 2022 Apr 1.","pmid":"35366963","type":"DERIVED"},{"citation":"Zhu M, Olson K, Kirshner JR, Khaksar Toroghi M, Yan H, Haber L, Meagher C, Flink DM, Ambati SR, Davis JD, DiCioccio AT, Smith EJ, Retter MW. Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies. Clin Transl Sci. 2022 Apr;15(4):954-966. doi: 10.1111/cts.13212. Epub 2022 Jan 7.","pmid":"34997701","type":"DERIVED"}],"start_date":{"date":"2015-01-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies","url":"https://clinicaltrials.gov/study/NCT02290951"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/elm-1-nct02290951"}